Royalty Pharma to present at upcoming investor conferences
Royalty Pharma will webcast two September 2026 healthcare conference presentations for investors, with replays available for at least 30 days.
Rhea-AI Summary
Royalty Pharma (RPRX) will participate in two investor conferences in September 2026.
Management is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDT, and at the BofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST.
Live webcasts and 30-day archives of these presentations will be available on the company’s investor “Events” page. Royalty Pharma describes itself as the largest buyer of biopharmaceutical royalties, with a portfolio of royalties on more than 35 commercial products and 17 development-stage product candidates.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
- Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDT
- BofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
How can investors access the Royalty Pharma conference presentations?
Webcasts of Royalty Pharma’s presentations at the September 2026 investor conferences will be accessible from the company’s investor “Events” page at https://www.royaltypharma.com/investors/events/.
How long will the Royalty Pharma conference webcasts remain available?
The company states that the webcasts will be archived and available for a minimum of thirty days.